NCT00066196已完成2 期
A Phase II, Randomized, Open-Label Study Evaluating The Antitumor Activity Of MEDI-522, A Humanized Monoclonal Antibody Directed Against The Human Alpha V Beta 3 Integrin, ± Dacarbazine In Patients With Metastatic Melanoma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 110
- 试验地点
- 49
- 主要终点
- Explore antitumor activity of MEDI-522 in patients with metastatic melanoma.
研究概览
简要总结
The primary objectives of this study are:
- To explore the antitumor activity of MEDI-522 ± DTIC in patients with metastatic melanoma.
- To determine the safety of MEDI-522 ± DTIC in this patient population.
详细描述
This is a Phase II, randomized, open-label, two-arm, multicenter study of MEDI 522 ± DTIC in previously untreated (other than adjuvant immunotherapy) patients with Stage IV metastatic melanoma (AJCC staging).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Explore antitumor activity of MEDI-522 in patients with metastatic melanoma.
时间窗: Screening and after every 2 cycles of treatment until disease progression. At least 4 weeks after a patient demonstrates response.
次要结局
- Determine the safety of MEDI-522 and/or DTIC in this patient population.(Every week until disease progression, and 30 days after disease progression.)
研究者
研究点 (49)
Loading locations...
相似试验
已完成
2 期
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate CancerProstate CancerNCT00072930MedImmune LLC150
已完成
2 期
A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric CancerGastric CancerNCT00952497ACT Biotech, Inc48
撤回
2 期
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon CancerColonic NeoplasmsColorectal NeoplasmsNCT05456165Gritstone bio, Inc.1
招募中
2 期
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and FirmonertinibNon-Small Cell Lung Cancer With EGFR MutationNCT06668103Abbisko Therapeutics Co, Ltd54
已完成
1 期
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT06055075Hoffmann-La Roche19